Intellia Therapeutics Inc (NASDAQ:NTLA) shares, rose in value on Thursday, March 27, with the stock price up by 1.08% to the previous day’s close as strong demand from buyers drove the stock to $8.40.
Actively observing the price movement in the last trading, the stock closed the session at $8.31, falling within a range of $8.11 and $8.43. The value of beta (5-year monthly) was 1.969. Referring to stock’s 52-week performance, its high was $28.23, and the low was $8.11. On the whole, NTLA has fluctuated by -22.22% over the past month.
With the market capitalization of Intellia Therapeutics Inc currently standing at about $869.55 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-26.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 11.39M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NTLA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of NTLA currently trading nearly -9.44% and -15.87% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 38.74, while the 7-day volatility ratio is showing 6.32% which for the 30-day chart, stands at 8.54%. Furthermore, Intellia Therapeutics Inc (NTLA)’s beta value is 2.18, and its average true range (ATR) is 0.75.
A comparison of Intellia Therapeutics Inc (NTLA) with its peers suggests the former has fared considerably weaker in the market. NTLA showed an intraday change of 1.08% in last session, and over the past year, it shrunk by -68.69%%.
Data on historical trading for Intellia Therapeutics Inc (NASDAQ:NTLA) indicates that the trading volumes over the past 10 days have averaged 3.14 and over the past 3 months, they’ve averaged 3.25 million. According to company’s latest data on outstanding shares, there are 102.03 million shares outstanding.
Nearly 5.89% of Intellia Therapeutics Inc’s shares belong to company insiders and institutional investors own 90.14% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 26.69 million shares as on 2025-03-14, resulting in a short ratio of 7.06. According to the data, the short interest in Intellia Therapeutics Inc (NTLA) stood at 2930.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 24.42 million. The stock has fallen by -27.96% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NTLA stock heading into the next quarter.
